Abstract Increasing evidence indicates that high levels of serum erythropoietin (Epo) can lessen ischemia-reperfusion injury in the heart and multiple cardiac cell types have been suggested to play a role in this Epo effect. To clarify the mechanisms underlying this cardioprotection, we explored Epo treatment of coronary artery endothelial cells and Epo cardioprotection in a Mus musculus model with Epo receptor expression restricted to hematopoietic and endothelial cells (DEpoR). Epo stimulation of coronary artery endothelial cells upregulated endothelial nitric oxide synthase (eNOS) activity in vitro and in vivo, and enhanced nitric oxide (NO) production that was determined directly by real-time measurements of gaseous NO release. Epo stimulated phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathways, and inhibition of PI3K, but not MEK activity, blocked Epo-induced NO production. To verify the potential of this Epo effect in cardioprotection in vivo, DEpoR-mice with Epo response in heart restricted to endothelium were treated with Epo. These mice exhibited a similar increase in eNOS phosphorylation in coronary artery endothelium as that found in wild type (WT) mice. In addition, in both WT-and DEpoR-mice, exogenous Epo treatment prior to myocardial ischemia provided comparable protection. These data provide the first evidence that endothelial cell response to Epo is sufficient to achieve an acute cardioprotective effect. The immediate response of coronary artery endothelial cells to Epo stimulation by NO production may be a critical mechanism underlying this Epo cardioprotection.
Introduction
Erythropoietin (Epo), a cytokine required for erythrocyte production, provides protection against ischemic injury in heart, vascular endothelium and other tissues of rodents [9, 14, 39] . In animal models of cardiac ischemia-reperfusion injury, Epo administered 24 h before or up to 24 h following coronary artery ligation reduced infarct size [9, 12, 16, 24, 25] . Epo could directly protect against apoptosis induced by hypoxia in cardiomyocytes in culture studies [12, 28] .
Epo has been reported to stimulate nitric oxide (NO) production by vascular endothelial cells mediated in part by induction and activation of endothelial nitric oxide synthase (eNOS/NOS3), particularly at reduced oxygen levels [3, 4] . However, Epo administered immediately prior to ischemia-reperfusion in the isolated rabbit heart model did not change nitrate and nitrite [34] . Subsequently, in the in vitro isolated rat heart ischemia-reperfusion model, it was shown that 24 h pretreatment with Epo provided protection dependent on NO [7] . The differences in these studies indicate that the Epo-cardioprotective activity may proceed via mechanisms that are both dependent and independent of NO. The important role of eNOS in Epo cardioprotection was illustrated by ischemia-reperfusion injury, where Epo cardioprotection was significantly diminished in eNOS -/--mice and appeared to be linked to phosphoinositide 3-kinases (PI3K) signaling [8, 29] .
EpoR in endocardium links Epo to normal heart and vascular development. Although the bulk of cardiac tissue mass is cardiomyocytes, the endothelial cell number in heart is about three times greater [5] . Embryonic EpoR -/--mice have severely affected angiogenesis and decreased complexity of vascular networks by day E10.5, exhibit ventricular hypoplasia at day E12.5 and show increased myocardium and endocardium apoptosis prior death in utero due to severe anemia at day E13.5 [21, 42, 46] . Epo stimulation of endothelial cells induced eNOS activation and NO production [4] , proliferation, chemotaxis and angiogenesis, and promoted endothelial progenitor cell migration [1, 39] . Mice overexpressing an Epo transgene exhibited elevated eNOS and plasma NO that contributes to prevention of cardiovascular disease such as hypertension and thromboembolism despite 80% hematocrit, and inhibition of NO synthase resulted in cardiovascular dysfunction and death [30] . The important role of eNOS in endothelial function suggests that Epo stimulation of endothelium contributes significantly to Epo cardioprotection. EpoR expression was also shown in cardiomyocytes and cardiac fibroblast cells [27, 41] . Epo stimulation of cardiomyocytes increased eNOS expression and NO production, which prevented cardiomyocytes from apoptosis [8] . Epo treatment in cardiac fibroblasts induced activation of JAK/STAT and ERK/MAPK signaling pathways [27] . Since cardiac fibroblasts contribute to post-ischemic remodeling and serve as a rich of source of cytokines, chemokines and growth factors, it was proposed that cardiac fibroblast cells contribute to Epo cardioprotection [27] . Hence, Epo-cardioprotective activity may proceed via multiple mechanisms involving diverse cell types.
To determine the contribution of cardiac endothelial response alone to Epo cardioprotection, mice were generated with endogenous EpoR expression restricted largely to hematopoietic and endothelial cells (DEpoR). DEpoR-mice that lack gross developmental defects show Epo cardioprotection in contrast to eNOS -/--mice that showed no Epo protection to myocardial ischemia-reperfusion injury. This suggests that the restoration of eNOS Epo response in endothelial cells via EpoR expression is sufficient to regain Epo cardioprotection as observed in wild type (WT) mice.
Methods

Animals
Mice with EpoR restricted to hematopoietic and endothelial cells (DEpoR) were generated by selective rescue of disrupted endogenous EpoR expression using a Tie2-Cre recombinase transgene [13] . TgEpoR-mice with EpoR expression restricted to erythroid cells were created using an EpoR transgene driven by the GATA-1-erythroid promoter on an EpoR -/-background [37] . C57Bl6/J WTmice were purchased (Jackson Laboratory) and eNOS -/--mice were originally from Paul Huang (Massachusetts General Hospital). Only male mice were used in current study due to the concern of sexual dimorphism in Epo production. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The NIDDK Animal Care and Use Committee approved all animal protocols.
Primary cell preparation
Ventricular cardiomyocytes, endothelial cells and fibroblasts were isolated from adult hearts from C57Bl/6 WTand DEpoR-mice (n = 3; 12 weeks old) by a modified perfusion method [36] . Briefly, After perfusion digestion, the ventricular tissue was minced, gently triturated and incubated in 5 ml of the same digestion buffer (the Tyrode's buffer containing 0.1 mmol/l CaCl 2 and Liberase Blendzyme 2) for 3 min at 37°C, the total dissociated cells were transferred into equal volume of the Tyrode's buffer (pH 7.4 in mmol/l: NaCl 140, KCl 4, MgCl 2 1, HEPES 5, D-glucose 10) containing 0.2 mmol/l CaCl 2 and 10 mg/ml bovine serum albumin (Sigma) to stop the digestion. After gradually adding CaCl 2 back to a final concentration of 1.2 mmol/l, cardiac endothelial cells were sorted using CD146 (LSEC) MicroBeads, mouse [#130-092-007] and a MACS Ò Cell Separation system (Miltenyi Biotec, Inc, CA) following guidelines from the manufacture and then cultured in EGM Ò -2MV microvascular endothelial cell growth medium (Lonza). The flow-through containing cardiomyocytes and fibroblast cells was resuspended into modified insulin-transferrin-selenite MEM buffer containing 100 U/ml penicillin-streptomycin, 2 mmol/l L-glutamine, 0.1 mg/ml bovine serum albumin, 10 mmol/l 2,3-butanedione monoxime, 10 lg/ml insulin, 5.5 lg/ml transferrin, 5 ng/ml selenium, plated in petri dishes and incubated at 37°C for 60 min. The attached fibroblast cells were grown in 10% CO 2 , in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 10% FCS (Hyclone) and 1% pen/strep (GIBCO). The cardiomyocytes were plated into laminin-coated six-well plate. Cells were cultured at 37°C for 48 h before they were processed for immunostaining and total RNA extraction. Neonatal cardiomyocytes from mice (2 days old) were isolated by collagenase/pancreatin digestion for 8-10 min at 37°C, gentle pipetting and transferring cell suspension to 50% bovine fetal serum (FBS), repeated three times. Cells were filtered and purified by selective sedimentation. Human coronary artery endothelial cells (HCAEC; Lonza, Walkersville, MD) were cultured for two to three passages in EGM Ò -2MV microvascular endothelial cell growth medium (Lonza).
NO measurement
Culture media nitrite levels for HCAEC, neonatal cardiomyocytes and HL-1 cells were performed using a modified Griess reaction. Nitrite and nitrate content were determined using the HPLC-based NOx analyzer ENO-20 (Eicom, San Diego, CA); nitrite and nitrate are separated on a HPLC column and then a Cd reducing column is used to reduce nitrate to nitrite. Free (NO) gas production from confluent cultures of HCAEC in a T75 flask was measured using chemiluminescence NOx analyzer (ECO Physics) with 21% O 2 (balance N 2 ) as carrier gas. Area under the peak indicating NO production was determined using Origin software. Cells were also pre-incubated (30-60 min) with inhibitors for nitric oxide synthase (L-N G -nitroarginine methyl ester), mitogenactivated protein kinase kinase (MEK) (U0126) and phosphoinositide 3-kinase (LY294002) prior to Epo treatment.
Analysis of protein expression
Proteins were extracted from endothelial cells and whole hearts, and concentration was determined using the BCA protein assay method (23227, Thermo Scientific, IL). After denaturation, protein was analyzed by gel electrophoresis (NuPAGE, Invitrogen Corp., Carlsbad, CA) using reducing conditions, transferred to nitrocellulose membranes (Invitrogen) and probed using rabbit IgG specific for eNOS (Sigma, Saint Louis, MO), AKT, ERK44/42, p38 mitogenactivated protein kinase (MAPK), phospho-eNOS (Ser1177), phospho-AKT (S473), phospho-ERK44/42, phospho-p38MAPK and iNOS (Cell Signaling Technology, Inc) as the primary and horseradish peroxide-labeled anti-rabbit immunoglobulin G (IgG) (GE Healthcare BioSciences Corp, Piscataway, NJ) as the secondary antibody, and visualized using ECL advance detection reagents (GE Healthcare Bio-Sciences Corp) and the FlourChemFC2 imager (Innotech, San Leandro, CA). Membranes treated with restore Western blot stripping buffer were re-probed using goat anti-b-actin polyclonal antibody and horseradish peroxide-labeled donkey anti-goat IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The Java image-processing program inspired by NIH image was used for quantitative analysis.
Gene expression analyses
Total RNA was extracted from cells and whole hearts using TRIzol (Invitrogen) and treated with Turbo DNase (Ambion, Austin, TX). RNA was reverse transcribed (MultiScribe Reverse Transcriptase, Applied Biosystems, Foster City, CA) and the resultant cDNA was used for Taqman Epo and eNOS phosphorylation in mouse heart and coronary artery endothelial cells WT-mice (n = 16), DEpoR-mice (n = 16) and eNOS -/--mice (n = 16) (16 weeks old) were treated with Epo (Epoetin alpha, Amgen) (n = 8) or saline (n = 8), respectively. Fifteen minutes after intravenous injection (tail vein) of Epo (500 U/kg in 100 ll saline) or saline, mice were killed and hearts were excised from five mice and immediately snap frozen in liquid nitrogen for later western blot analysis. Hearts of three mice from each group were perfused with cold PBS buffer then cold 4% paraformaldehyde in PBS for preparation of paraffin sections.
Immunohistochemical and immunofluorescent staining
Paraffin sections were dewaxed, processed for antigen retrieval using citrate-based buffer (Vector Laboratories) and treated with hydrogen peroxidase to block endogenous peroxidase activity. Following blocking with normal goat serum, sections were incubated with primary antibodies specific for eNOS (Sigma), and phospho-eNOS (Ser1177; Cell Signaling Technology), and then with horseradish peroxidase-conjugated secondary antibody (Zymed). 3,3 0 -Diaminobenzidine tetrahydrochloride (DAB) Enhanced Liquid Substrate System (D6815, Sigma-Aldrich, Inc.) was used as peroxidase substrate for color development and methyl green was used as a nuclear counterstain. Cardiac endothelial cells cultured in six-well plates were rinsed with cold PBS and fixed in 4% paraformaldehyde/PBS, pH 7.4, at 4°C for 30 min. After rinsing in cold PBS, the cells were incubated in 10% goat serum in PBS for 1 h at room temperature to block non-specific protein-protein interaction, then incubated with primary antibody, rat anti-mouse PECAM-1 (5 lg/ml) (CBL1337, Cymbus Biotechnology) overnight at 4°C. The secondary antibody was TRITCconjugated goat anti-rat IgG used at 1/500 dilution for 1 h at room temperature.
Myocardial ischemic-reperfusion injury
Epo (10,000 U/ml; Amgen Inc., Thousand Oaks, CA) was diluted in normal (0.9%) saline to a dose of 4,000 U/kg in 200 ll. Normal saline or Epo was injected intraperitoneally 15 min prior to myocardial ischemia. Surgical ligation of the left coronary artery (LCA) on mice was performed following administration of ketamine/pentobarbital anesthesia, intubation and connection to a rodent ventilator and median sternotomy as described previously [11] . After 45 min (30 min for eNOS -/-) of LCA ischemia, mice were reperfused for 24 h. All mice analyzed survived this 24 h ischemic-reperfusion injury procedure. The assessment of left ventricular area-at-risk (AAR) and infarct size (Inf) was performed as used previously [11] .
Statistical analysis
Statistical analyses are expressed as mean ± STD or SEM values as indicated in the figure legends. Statistical significance was evaluated by Student's t test or one-way ANOVA with a Tukey's Multiple Comparison Test.
Results
Epo induction of NO in coronary artery endothelial cells
The real-time release of NO in primary HCAEC was monitored during treatment with saline as baseline using a sensitive chemiluminescence NOx analyzer (Fig. 1a) . Epo treatment resulted in an induction of NO release beginning at 15-20 min, reaching a peak at 15 min after the start of NO release and returning to baseline at about 30 min (Fig. 1b) . Epo induction of NO was lost with L-N G -nitroarginine methyl ester (L-NAME) treatment (Fig. 1c, d ), suggesting that Epo-induced NO production is eNOSdependent. Although inducible nitric oxide synthase (iNOS) has also been demonstrated to generate NO in endothelial cells, we did not detect iNOS expression in these cells.
As an alternate measure of NO production, nitrite/nitrate levels determined by a modified Griess reaction were examined. NO production in coronary artery endothelial cells at 21% and 2% O 2 was comparable. Epo-induced NO production at 2% O 2 was statistically significant for Epo concentration at 1-10 U/ml with an increase of twofold or more at 4 h (Fig. 1e) . Epo response appeared to be optimum at 5 U/ml with no further increase in NO production at 10 U/ml. L-NAME treatment abrogated the Epo induction of NO, confirming that NO production is mediated via activation of eNOS. These results are analogous to our previous observation of Epo response in human umbilical vein endothelial cells (HUVEC) that increased at low oxygen tension where EpoR expression was upregulated [3, 4] .
Epo stimulation in coronary artery endothelial cells
The analysis of Epo/EpoR downstream signaling pathways in HCAEC by Western blotting revealed Epo-stimulated phosphorylation of AKT, becoming significant at 15 min, while the level of AKT remained unchanged (Fig. 2a-c) . Epo-induced phosphorylation of AKT increased continuously even at 4 h following Epo stimulation. Epo also activated ERK phosphorylation. Phosphorylation of ERK44 and ERK42 was increased at 5 min following Epo stimulation and was downregulated to a level close to baseline at 30 min while total ERK44 and ERK42 expression remained unchanged (Fig. 2d-h ). In contrast to Epo stimulation of AKT and ERK phosphorylation, no differences in p38 mitogen-activated protein kinase (MAPK) or phosphorylated p38 MAPK (p-p38MAPK) levels were observed with Epo treatment (Fig. 2i-k) .
Epo activation of eNOS in coronary artery endothelial cells
To confirm that Epo induces NO production through stimulation of eNOS activity, eNOS expression and/or phosphorylation in Epo-treated HCAEC was examined by Western blotting. Epo treatment induced phosphorylation of eNOS at Ser1177, peaking at 15 min and returning to baseline level by 240 min (Fig. 3a, b) . Total eNOS expression was not affected (Fig. 3a, c) . The timing of Epo-stimulated increase in eNOS activity indicated by eNOS phosphorylation was consistent with the NO release detected in real-time measurement (Fig. 1b) . PI3K/protein kinase B (AKT)-dependent phosphorylation of eNOS promotes NO production [15] and Epo stimulation of endothelial cells has been linked to PI3K/AKT signaling [39] . Treatment with PI3K inhibitor, LY294002, blocked Epo induction of NO (Fig. 3d, f) . In contrast, although Epo activated the MEK/ERK pathway and stimulated ERK phosphorylation, treatment with the MEK inhibitor, U0126, did not inhibit Epo-stimulated NO production (Fig. 3e, f) . These results suggest that Epo-induced NO production in coronary artery endothelial cells is eNOS dependent and proceeds via the PI3K/AKT signaling pathway. Interestingly, Epo induced a transient phosphorylation of eNOS but had a more prolonged effect on AKT phosphorylation, suggesting that dephosphorylation of eNOS is initiated by a mechanism independent of AKT activity [18] . Alternatively, the possibility that activated AKT triggers dephosphorylation of eNOS (via activation of a phosphatase, for example) as a negative feedback mechanism cannot be excluded.
Epo induced eNOS phosphorylation in mouse coronary artery endothelial cells
To verify Epo induction of eNOS activity in heart in vivo, WT-mice were treated with Epo or saline. As observed in the culture studies, phosphorylated eNOS (phospho-eNOS) in heart from Epo-treated mice increased markedly compared with saline-treated mice at 15 min after Epo injection, although eNOS expression was not changed (Fig. 4a, b) . Immunohistochemical analysis of heart sections from Epo-treated mice localized the induction of eNOS phosphorylation in coronary artery endothelial cells but not in other tissues (Fig. 4e) . Epo treatment also promoted eNOS phosphorylation in heart of DEpoR-mice with no change in eNOS expression, similar to the levels observed in WT-mice (Fig. 4a, b) . Immunostaining for eNOS and phospho-eNOS in heart of DEpoR-mice was comparable to that of WT-mice with marked increase of phospho-eNOS staining in coronary artery endothelium after Epo treatment (Fig. 4e) . In contrast, Epo treatment in eNOS -/--mice showed no increase in either eNOS or phosphorylated eNOS (Fig. 4a, b, e) .
Quantification of EpoR mRNA shows EpoR expression in heart about 10 times lower than that in spleen, a hematopoietic tissue in mice. EpoR expression was even lower in isolated cardiomyocytes and cardiac fibroblasts from adult WT-mice ( Fig. 4c ; Online resource Figure S2 ). In contrast to Epo stimulation of NO production in coronary artery endothelial cells (Fig. 1) , Epo treatment of primary neonatal cardiomyocytes (Fig. 4d) and a cardiomyocyte cell line, HL-1 (data not shown), did not stimulate NO production as determined by a modified Griess reaction. In DEpoR-mice, EpoR expression in spleen and heart was similar to that in WT-mice (Fig. 4c) . However, lack of EpoR expression in isolated adult cardiomyocytes and cardiac fibroblasts from DEpoR-mice illustrates the restriction of EpoR expression to hematopoietic and endothelial tissue ( Fig. 4c ; Online resource Figure S2 ). These data indicate that Epo induction of phospho-eNOS in heart of DEpoR-mice is also due primarily to an endothelial response rather than a direct effect of Epo on cardiomyocytes. The comparability of Epo effect in heart of WT-and Fig. 1 Epo effect on NO production in coronary artery endothelial cells (HCAEC). Diffusion of NO release from the culture medium into the gas phase was directly monitored for primary coronary artery endothelial cells treated with a saline (S), b Epo (5 U/ml) and c Epo plus L-NAME (pre-incubated at 1 mmol/l for 30 DEpoR-mice suggests that coronary endothelium is the primary and/or initial target of Epo in inducing phosphorylation of eNOS.
Exogenous Epo in ischemia-reperfusion injury
Our analysis on Epo effect in coronary artery endothelial cells in both in vitro and in vivo conditions suggests an essential role of endothelium in Epo cardioprotection. To clarify this hypothesis, age-and gender-matched WT-and DEpoR-mice were divided into two groups each to assess ischemia-reperfusion injury with and without Epo treatment (Fig. 5a, c) . Plasma NO levels were determined by measuring nitrite/nitrate. No difference in plasma NO level among the groups was identified. Mice were treated with Epo 15 min prior to LCA occlusion and evaluated after 24 h of reperfusion, prior to the expected Epo-induced increase in hematocrit. WT-and DEpoR-mice treated with Epo showed no change in hematocrit after 24 h (Online resource Figure S3 ). The AAR relative to the entire left ventricle (LV) was similar in all of the groups (Fig. 5a-c) . In WT-mice, Epo decreased the infarct size (Inf) relative to the AAR (Inf/ AAR) and infarct size relative to the entire LV (Inf/LV) by 44% when compared to vehicle treatment (Fig. 5a, b) . DEpoR-mice behaved analogous to age-and sex-matched WT-mice when subjected to heart ischemia-reperfusion injury (Fig. 5b, c) . Epo treatment in DEpoR-mice provided cardioprotection with reduction in infarct size at levels observed for WT-mice (Fig. 5a-c) . This suggests that preservation of endothelial response to Epo stimulation is sufficient for achieving Epo cardioprotection in this model of myocardial ischemia-reperfusion injury.
In contrast to WT-and DEpoR-mice, Epo cardioprotection was not observed in eNOS -/--mice (Fig. 4d) . In these animals, LV ischemia for 30 min and reperfusion for 24 h resulted in similar extent of infarction relative to the AAR and the LV. Treatment with Epo did not significantly improve outcome when eNOS was no longer a contributing factor in the Epo effect. These data provide strong evidence that Epo response in endothelial cells is essential for cardioprotection of exogenous Epo that includes the upregulation of eNOS activity and induction of NO production. Endogenous Epo signaling did not appear to provide additional protection to ischemia-reperfusion injury. Hematopoietic rescue of the EpoR -/-phenotype (TgEpoR) resulted in viable mice with no gross morphological defect of heart development [37] . At 5 months we observed no difference in myocardial ischemia-reperfusion injury between untreated WT-and TgEpoR-mice (Online resource Figure S1 ). The damage in myocardial ischemia-reperfusion injury in TgEpoR-mice was not affected by loss of endogenous Epo signaling in non-hematopoietic tissue.
Discussion
Using a mouse model with EpoR expression restricted to hematopoietic and endothelial cells, we show specifically that the Epo effect in cardiac endothelial cells preserved the acute (24 h) Epo cardioprotection comparable to WTmice. This effect is unlikely due to hematopoietic response since we did not detect changes in hematocrit in the 24-h period following Epo administration that was used for the ischemic-reperfusion injury model. In culture, we previously observed Epo induction of eNOS activity in endothelial cells from select vascular beds. We demonstrate here for the first time the kinetic changes of NO production in coronary artery endothelial cells following Epo stimulation. The timing of Epo-induced NO release beginning at 15 min after stimulation appears concomitant with the change in eNOS activity and is dependent on the PI3K/ AKT signaling pathway. These findings support the observation of PI3K-dependent Epo protection in rat using the perfused isolated heart model and in vivo [6, 10] . In animal studies, we also demonstrate that change in eNOS phosphorylation in cardiac endothelial cells was evident 15 min after Epo administration. The importance of eNOS in Epo activity is further suggested by the lack of Epo cardioprotection in eNOS -/--mice. The evidence from the current study demonstrates the Epo effect on coronary artery endothelial cells to stimulate eNOS activity and NO production and strongly suggests that endothelial response is sufficient to provide acute Epo cardioprotection. NO is an important signaling molecule released from endothelial cells and contributes to a variety of fundamental cardiac activities. NO released from coronary artery endothelial cells can diffuse to coronary smooth muscle and initiate vasodilation of coronary arteries, which serves as a mediator of cardiac blood flow. In the capillaries, NO can diffuse to the cardiomyocytes, to affect timing of relaxation and myocardial oxygen consumption [33] . A number of studies have shown that enhancing NO availability by administration of NO donor reduces myocardial infarction size and improves the outcome of ischemia/ reperfusion injury. This protective effect is attributed to contributions of exogenous NO to early preconditioninglike protection and induction of late phase preconditioning, involving both PI3K/AKT and ERK1/2, the so-called reperfusion injury salvage kinase (RISK) pathways. Although endogenous NO is not necessary for early phase protection of ischemia-induced preconditioning, upregulation of NO production by eNOS is required for cardioprotective effects of late phase ischemic preconditioning [17, 20, 32, 44] . These NO associated activities suggest the therapeutic potential of mechanisms that increase NO levels in cardioprotection. Here, we observed a rapid Epoactivation of eNOS and the corresponding NO release in coronary artery endothelial cells. Epo treatment induced comparable cardioprotection against ischemia/reperfusion injury in both WT-and DEpoR-mice where EpoR expression in heart is restricted in endothelial cells, but is abrogated when eNOS is ablated (eNOS -/--mice). This indicates that Epo cardioprotection is eNOS dependent and requires endothelial stimulation by Epo, which may induce preconditioning-like effect through stimulating NO production. Unlike eNOS, iNOS is not constitutively expressed and its activity is regulated at the level of expression [22] . The lack of iNOS expression in our coronary artery endothelial cells after Epo treatment indicates that iNOS does not contribute to the immediate endothelial response observed here.
Long-term Epo treatment increased constitutive eNOS expression and NO production in culture [3, 4] and transgenic mice overexpressing Epo exhibit elevated eNOS and NO [30] . However, the rapid response of coronary artery endothelial cells to Epo stimulation by increasing NO production in our current study is a result of increased activity of eNOS caused by phosphorylation without a change in overall eNOS expression. The data presented here support a key role for endothelial production of NO in Epo cardioprotection during the first 24-h period in this model of ischemia-reperfusion injury. A sustained high level of Epo may also help recovery from ischemiareperfusion injury through its pro-angiogenic activity, another major effect of Epo on endothelial cells [21] . Evidence that Epo treatment mobilizes endothelial progenitor cells from bone marrow and contributes to endothelial regeneration [39] may support a long-term recovery from heart infarction beyond the 24-h period of ischemia-reperfusion injury model used here. In adult mice, EpoR deficiency in non-hematopoietic tissue caused impaired mobilization of endothelial progenitor cells and accelerated development of hypoxia-induced pulmonary hypertension [26, 31] . However, comparison between WTand TgEpoR-mice suggests that endogenous Epo does not provide further protection in mice subjected to the 24-h ischemia-reperfusion injury. In contrast to the report of greater susceptibility to cardiac ischemia/reperfusion injury in young TgEpoR-mice [38] , the similarity in response to ischemia-reperfusion injury observed here among WT-, DEpoR-and TgEpoR-mice without Epo treatment (Online resource Figure S1 ) suggests a minimal or no cardioprotective effect of endogenous Epo, unlike that observed for exogenous Epo treatment. Epo binding to its dimeric receptor on the cell surface results in activation of cytoplasmic associated JAK2 and phosphorylation of multiple tyrosines in the tail region of EpoR that triggers downstream signaling pathways such as PI3K/AKT and MEK/ERK. In endothelial cells, growth factors such as VEGF can stimulate AKT-mediated phosphorylation of eNOS [45] . Blocking this signaling pathway in isolated whole heart perfusion model, the protective effect of Epo was significantly attenuated [10] . We observed that Epo-induced phosphorylation of eNOS (Ser1177) and NO production in coronary artery endothelial cells were blocked by PI3K inhibitor LY294002, providing evidence that the PI3K/AKT signaling pathway contributes specifically to Epo-induced endothelial response. Phosphorylation of eNOS via ERK44/42 has been suggested for adenosine induction of NO [43] . While we found Epo-stimulated ERK44/42 phosphorylation, this was not affected by blocking ERK activity with U0126. Estrogen activation of eNOS mediated by estrogen receptor alpha is p38 MAPK-dependent [2] , but we found no change in phospho-p38MAPK.
A direct protective effect of Epo on cardiomyocytes and a potential cardioprotection by cardiac fibroblast cells stimulated by Epo have been suggested in previous studies; however, the lack EpoR expression in cardiomyocytes and cardiac fibroblast cells of DEpoR-mice suggests that the endothelial Epo response is the major contributor to Epo cardioprotection during the initial 24 h of ischemiareperfusion injury. While we previously observed highlevel EpoR expression and Epo protection in primary neural progenitor cells and neurons [13, 46] , we found low level of EpoR expression in primary cardiomyocytes. Lack of Epo-stimulated eNOS response and Epo binding in cardiomyocytes was also observed during the initial 24-h Epo protective response in a rat heterotopic heart transplantation model [23] . In contrast, direct Epo response by cardiomyocytes was previously reported for primary cardiomyocytes cultures treated with higher Epo concentrations (20-40 U/ml), but only after 24 h of Epo treatment, and eNOS-dependent Epo-protection from norepinephrine toxicity was observed at 48 h [8] . This provides further evidence that Epo-stimulated cardioprotective eNOS response during the initial 24 h is primarily mediated by endothelial cells while cardiomyocytes have been shown to contribute importantly to the late phase cardioprotection of Epo [40] . Although we show that endothelial Epo response is sufficient to provide acute protection in heart of DEpoR-mice, multiple factors may contribute to long-term Epo cardioprotection in WT-mice and involve diverse cell types. Studies with other animal models of ischemia-reperfusion injury are warranted to fully understand the potential and limitations of EPO cardioprotection, including the role of RISK activation, for translation to a clinical setting [19, 35] .
Epo stimulation of NO production in endothelial cells such as HUVEC and human umbilical artery and bone marrow microvascular endothelial cells was mediated by endothelial eNOS activation [4] . Epo induction of eNOS activity and endothelial NO production is likely an effect on multiple organ sites. This raises a possibility of systemically increased NO level following Epo treatment in vivo that may further contribute to Epo protection. With EpoR expression restricted to endothelial cells, EpoR expression in cardiomyocytes and direct cardiomyocyte response to Epo did not appear to be necessary for Epo cardioprotection in this mouse ischemia-reperfusion injury model. Whether EpoR expression in cardiomyocytes or other cell types without expression in endothelial cells is sufficient to provide a protective Epo response to cardiac injury requires further investigation.
